M

ultiple myeloma patients treated with an experimental CAR-T therapy developed by Bluebird Bio and licensed to Celgene went nearly one year before their cancer progressed, according to updated study results presented Friday night at the annual meeting of the American Society of Clinical Oncology.

The durability of responses to Bluebird’s CAR-T, called BB2121, is a focal point for investors at this year’s ASCO meeting. The exact number — median progression-free survival of 11.8 months — effectively meets the lower end of expectations, which ranged as high as 15 months, based on analyst reports.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Prolong a dying mothers life by a year
    Adam bashes.
    This vile blogger is a disgrace and karma will not
    Be kind.

    Hopefully one day someone in his family needs a drug to live ONE YEAR MORE

    and that company tells the basher Adam F U

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy